In:
International Journal of Cancer, Wiley, Vol. 148, No. 6 ( 2021-03-15), p. 1478-1488
Abstract:
In metastatic pancreatic cancer (mPC), chemotherapy with nab‐paclitaxel plus gemcitabine has shown significant survival benefits. However, less attention has been paid to quality of life (QoL) for these patients. In this prospective study, the authors found that, due to the aggressive nature of mPC, QoL declined rapidly for most patients. But surprisingly, as many as 41% of patients were able to maintain their baseline QoL at six months. Thus, while overall results remain poor, it does appear possible to stabilize QoL for a subset of patients receiving this first‐line combination chemotherapy.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8